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Objective: Citrullinemia type 1 (CTLN1) is an inherited metabolic disease
affecting the brain which is detectable by newborn screening. The clinical spec-
trum is highly variable including individuals with lethal hyperammonemic
encephalopathy in the newborn period and individuals with a mild-to-moderate
or asymptomatic disease course. Since the phenotypic severity has not been pre-
dictable early during the disease course so far, we aimed to design a reliable
disease prediction model. Methods: We used a newly established mammalian
biallelic expression system to determine residual enzymatic activity of argini-
nosuccinate synthetase 1 (ASS1; OMIM #215700) in 71 individuals with
CTLN1, representing 48 ASS1 gene variants and 50 different, mostly compound
heterozygous combinations in total. Residual enzymatic ASS1 activity was cor-
related to standardized biochemical and clinical endpoints available from the
UCDC and E-IMD databases. Results: Residual enzymatic ASS1 activity corre-
lates with peak plasma ammonium and L-citrulline concentrations at initial
presentation. Individuals with 8% of residual enzymatic ASS1 activity or less
had more frequent and more severe hyperammonemic events and lower cogni-
tive function than those above 8%, highlighting that residual enzymatic ASS1
activity allows reliable severity prediction. Noteworthy, empiric clinical practice
of affected individuals is in line with the predicted disease severity supporting
the notion of a risk stratification-based guidance of therapeutic decision-making
based on residual enzymatic ASS1 activity in the future. Interpretation: Resid-
ual enzymatic ASS1 activity reliably predicts the phenotypic severity in CTLN1.
We propose a new severity-adjusted classification system for individuals with
CTLN1 based on the activity results of the newly established biallelic expression
system.
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Introduction
Citrullinemia type 1 (CTLN1) is an autosomal recessive
urea cycle disorder caused by deficiency of the cytosolic
enzyme argininosuccinate synthetase 1 (ASS1-D; MIM
#215700) due to pathogenic variants in the ASS1 gene
located on chromosome 9q34.11. CTLN1 is one of the
most common urea cycle disorders (UCDs) with an esti-
mated overall incidence of 1 in 250,000 individuals.1,2
The heterogeneous clinical presentation of individuals
with CTLN1 includes severe and life-threatening hyper-
ammonemic events (HAEs) within the first 28 days of life
(early onset, EO), a more variable phenotype presenting
after the neonatal period (late onset, LO), and individuals
with mild or no symptoms even in the absence of specific
therapy. These are the major cornerstones of current clin-
ical classification (EO, LO, asymptomatic) in individuals
with CTLN1.3,4 A meta-analysis recently demonstrated
that neonatal mortality in EO CTLN1 is still high and has
not significantly improved for more than three decades,
despite implementation of pharmacologic and extracorpo-
real detoxification for emergency treatment of HAEs, and
low-protein diet as well as nitrogen scavengers for main-
tenance treatment.5 Timely liver transplantation (LTx)
might prove beneficial for severely affected individuals
with regard to their cognitive outcome.6
Large observational natural history studies of UCDs in
North America [Urea Cycle Disorders Consortium
(UCDC; https://www.rarediseasesnetwork.org/cms/ucdc)]
and Europe [European registry and network for
intoxication type metabolic disease (E-IMD; https://
www.eimd-registry.org/)] have identified clinical variables,
such as early disease onset, or biochemical variables, such
as high initial peak plasma ammonium concentration
(NH4
+
max), to be correlated with poor long-term
outcome.7–10 However, phenotypic severity has not been
predictable early during the disease course so far. This
has hampered the development of severity-adjusted thera-
peutic strategies to improve the health outcomes. The
increasing identification of individuals with a potentially
benign disease course by newborn screening programs for
CTLN1 supports the need for a reliable prediction model
to reduce the risk of over- and undertreatment. Based on
a systematic data collection, currently more than 100 dis-
ease-causing ASS1 genetic variants are known; however,
the impact of the genotype on the phenotypic presenta-
tion remains insufficiently understood.11 Given that resid-
ual enzymatic activities have already been reported to
predict disease severity and survival rates in other inborn
errors of metabolism, such as Farber disease and
mucopolysaccharidosis type IIIA and VII,12–14 we hypoth-
esized that ASS1 enzyme activity may correlate with dis-
ease severity in CTLN1.
Furthermore, since we recently demonstrated that diag-
nosis and therapy are important, but not the only factors
that have an impact on the cognitive outcome in urea cycle
disorders,6 we hypothesize that the underlying genotypic
variability might have an important effect on the clinical
outcome. Thus, we evaluated whether the residual enzy-
matic ASS1 activity, as determined by an innovative and
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newly established mammalian biallelic expression system,
can predict the clinical disease course and neurological out-
come. To this end, we systematically investigated all
reported exonic variants from the worldwide largest cohort
of individuals with CTLN1 reported in the UCDC and E-
IMD patient registries and correlated data with the individ-
uals’ biochemical, clinical, and neurological follow-up data.
Materials and Methods
Eligibility criteria
Only individuals with CTLN1 confirmed by biallelic
pathogenic variants in ASS1 who were enrolled in the
observational longitudinal studies UCDC (NCT00237315)
and E-IMD were included in this analysis. The data
model of both registries, information on written informed
consent as well as the follow-up protocols used have been
previously described in detail.2,6 Requirements set forth
by the ICMJE (International Committee of Medical Jour-
nal Editors) were met. All procedures followed were in
accordance with the ethical standards of the Helsinki Dec-
laration of 1975, as revised in 2013. Data were retrieved
from the UCDC and E-IMD electronic databases with the
cut-off date for data retrieval being October 10, 2018.
The UCDC database is registered at the US National
Library of Medicine (https://clinicaltrials.gov), whereas
the E-IMD registry is recorded on the German Clinical
Trials Register (https://www.drks.de).
Plasmids
To generate the tagged wildtype ASS1 expression vectors,
the ASS1 coding sequence was amplified by PCR with
MYC- or FLAG-tags introduced at the C- or N-terminus
using specific primer pairs and inserted into the BamHI
and NotI restriction sites in the open-reading frame of
the eukaryotic expression vector pcDNA5 (Thermo Fisher
Scientific). Pathogenic ASS1 gene variants observed in
individuals with CTLN1 within the E-IMD and UCDC
registries were introduced into the tagged ASS1 expression
vectors using the QuickChange II site-directed mutagene-
sis kit (Agilent) according to the manufacturer’s protocol.
The wildtype ASS1 expression vectors and the correct
insertion of the mutations were confirmed by Sanger-se-
quencing. The pSV-b-galactosidase control vector (Pro-
mega) was kindly provided by N. Himmelreich
(Heidelberg University, Germany).
Cell culture and transfections
COS-7 cells were maintained as adherent cell cultures in
10 cm petri dishes in DMEM medium (Thermo Fisher
Scientific) supplemented with 10% heat-inactivated fetal
bovine serum in a humified incubator at 37°C and 5%
CO2. COS-7 cells were transfected with 2.5 µg of each
FLAG- and MYC-tagged ASS1-plasmid and 1 µg of b-
galactosidase reporter plasmid using Lipofectamin 2000
reagent (Thermo Fisher Scientific) according to the man-
ufacturer’s instructions. After 48 h, cells were washed two
times with ice-cold phosphate-buffered saline (PBS), lysed
and the lysates were utilized to perform qRT-PCR, west-
ern blotting, and ASS1 enzyme assay.
qRT-PCR
RNA was extracted by standard procedure with TRIzol
reagent (Invitrogen). Equal amounts from each sample
(500–800 ng) were used for cDNA syntheses applying the
Maxima first strand cDNA synthesis kit (Thermo Fisher
Scientific). Real-time qPCR was performed on a CFX
ConnectTM 180 Real-Time cycler (Biorad) (denaturation
step: 95°C for 25 sec, annealing and elongation step: 60°C
for 30 sec) using SensiFast SYBRTM Hi-ROX mix (Bioline)
with the following primers:
Tagged-ASS1-plasmids (N-terminus)
N-FLAG_forward: 50-CTACAAAGACGATGACGACAAG-30
N-MYC_forward: 50-GAAGAGGATCTGGGAGGTTCAGG-30
N-tag_reverse: 30-CTTCTTCCTGGCTTCCTCG-50
Tagged-ASS1-plasmids (C-terminus)
C-tag_forward: 50-CCCACTGTCTCTCTACAATGAGG-30
C-FLAG_reverse: 30-GTCGTCATCGTCTTTGTAGTCG-50
C-MYC_reverse: 30-GTTTTTGTTCGCTGCCTCCTG-50
b-Actin
Actin_forward: 50-CAACCTTCCTTCCTGGGCAT-30
Actin_reverse: 30-GATTTTCATCGTGCTGGGCG-30
The expression level of b-actin was used for normalization.
Western blot
Forty eight hours after transfection, COS-7 cells were
washed two times in ice-cold PBS and lysed in 19 ice-
cold radioimmunoprecipitation buffer (600 mmol/L
NaCl, 100 mmol/L TRIS-HCl pH 7.4, 10 mmol/L EDTA,
2% Triton X-100, 0.2% SDS, 1% sodium deoxycholate)
followed by additional sonification. Hereafter, lysates were
centrifuged at 13,000 x g and 4°C for 10 min, and super-
natants were used for Western blotting according to stan-
dard laboratory protocols. For protein visualization,
membranes were probed with the following primary
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antibodies: anti-FLAG (1:2000, BioLegend), anti-MYC
(1:2000, Cell Signaling) and anti-b-Actin (1:2000, Sigma-
Aldrich).
Spectrophotometric analysis of the ASS1
enzyme
Purified citrate synthase, malate dehydrogenase, and fu-
marase from porcine heart were purchased from Sigma-
Aldrich. Recombinant C-terminally FLAG-tagged argini-
nosuccinate lyase protein was obtained from Creative Bio-
mart. ASS1 enzyme activity was determined in transfected
COS-7 cell lysates (triplicates) in a buffer containing
10 mmol/L potassium phosphate, 10 mmol/L TRIS-HCl,
2 mmol/L citrulline, 600 mU/mL of argininosuccinate
lyase, 650 mU/mL fumarase, 660 mU/mL malate dehy-
drogenase, 400 mU/mL citrate synthase, 2 mmol/L aspar-
tic acid, 330 µmol/L NAD, 100 µmol/L acetyl-CoA and
2 mmol/L ATP, which was adjusted to pH 7.4 (25°C).
ASS1 enzyme activity was determined as NAD reduction
at k = 340–400 nm. Lysates of COS-7 transfected with
empty pcDNA5 vector served as negative control. Nega-
tive control values were subtracted from ASS1 activities
to adjust for ASS1 background activity.
To control for transfection efficacy, the ASS1 activi-
ties were normalized to the b-galactosidase activity in
each sample as determined by the b-galactosidase
enzyme assay system (Promega) according to the manu-
facturer’s instructions. The adjusted ASS1 activities were
normalized to the protein content in the respective
samples. Residual activities are depicted as percentage
of total (%) by dividing the normalized ASS1 activity
of a specific mutational combination (homozygous/com-
pound heterozygous) by the normalized wildtype ASS1
activities.
Clinical variables used for data analyses
Data on the following numerical clinical variables were
collected: NH4
+
max, peak plasma L-citrulline concentra-
tion, number of HAEs (with NH4
+
max > 100 µmol/L) per
year of observation (defined as time between date of birth
and last regular visit), NH4
+
max during the most severe
HAE, and cognitive SDS at the most recent visit being
calculated using the normative data from the standardiza-
tion sample of each cognitive test. The most recent visit
was chosen since this is the latest developmental data on
patients which most likely represents the true outcome.
For each Hamburg-Wechsler-Intelligenztest f€ur Erwach-
sene (n = 1/34), Wechsler Adult Intelligence Scale (n = 1/
34), Wechsler Abbreviated Scale of Intelligence (n = 7/
34), Wechsler Intelligence Scale for Children (n = 3/34),
and Wechsler Preschool and Primary Scale of Intelligence
(n = 4/34) full scale IQ was selected. For Bayley Scales of
Infant Development (n = 15/34) mental developmental
index and cognitive scale were used. For Adaptive Behav-
ior Assessment System (n = 3/34) the general adaptive
composite was used.15
Data on following categorical clinical variables was also
used for this study: disease onset (EO, LO, asymp-
tomatic), presence or absence of movement disorder (dys-
tonia and/or chorea and/or ataxia), tone change
(muscular hypotonia and/or muscular hypertonia and/or
spasticity), special education (self-contained class as well
as any supportive services), hepatocellular injury (alanine
aminotransferase ≥ 250 U/L or aspartate aminotrans-
ferase ≥ 250 U/L), liver transplantation (LTx), and kidney
dysfunction [full age spectrum glomerular filtration rate
(FAS-GFR) ≥ 90 mL/min/1.73 m2 vs. FAS-GFR < 90 mL/
min/1.73 m2].16,17
For symptomatic individuals with reported HAE during
the initial presentation/decompensation, biochemical data
(NH4
+
max and peak plasma L-citrulline concentration)
represent the highest value prior to initiation of treat-
ment. For symptomatic CTLN1-individuals without
reported HAE during initial presentation, NH4
+
max was
defined as upper limit of normal range (50 µmol/L). For
asymptomatic individuals, NH4
+
max and peak plasma L-
citrulline concentrations represent highest reported fol-
low-up values during the observation period as conserva-
tive approach; only untreated asymptomatic CTLN1-
inviduals were considered for analysis. We investigated
the impact of the cumulative residual ASS1 enzymatic
activity as determined by the established biallelic expres-
sion system on clinical outcome parameters outlined
above. Mortality could not be examined due to a low
number of deceased individuals within the observation
period.2
Data availability statement
The datasets generated and analyzed during the current
study are not publicly available due to existing data pro-
tection laws. Furthermore, data ownership is retained by
the members of the UCDC and E-IMD consortia making
data available for specific research purposes. Data avail-
ability is subject to the consent of both consortia upon
request.
Statistical analysis
All analyses were performed using R (http://www.r-projec
t.org). To evaluate the relationship between a continuous
dependent variable and the cumulative residual enzymatic
ASS1 activity as predictor variable, a linear regression or
generalized additive regression model (GAM) with
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automated smoothing selections was used.18 In GAM, the
linear relationship between the response variable and pre-
dictors are replaced by nonlinear smooth functions to
evaluate an apparently non-linear relationship between
dependent and predictor variable. The R package “mgcv”
was used to fit GAM regressions. To compare a numeric
dependent variable between two groups, a t-test with
Welch correction was applied. We used unbiased recur-
sive partitioning to determine cut-off values for the
impact of cumulative residual enzymatic ASS1 activity on
outcome variables.19 Two groups were compared with a
t-test with Welch correction. P values reported were two-
sided. P ≤ 0.05 was considered statistically significant.
Results
Description of study population and ASS1
protein functions
We determined systematically enzymatic ASS1 activities
in 71 individuals with CTLN1, representing 48 ASS1
gene variants and 50 different combinations in total.
Results of qRT-PCR and Western Blot analyses of ASS1
mRNAs and proteins are depicted in Figures S1 and
S2. Residual enzymatic ASS1 activities per variant com-
bination are illustrated in Figure S3. Detailed descrip-
tive characteristics of the study population for each
subsequent analysis are shown in Tables S1 and S2. Of
note, residual enzymatic ASS1 activity as determined in
the biallelic expression system corresponded well with
the enzymatic activity measured in patient fibroblasts
and reported in the UCDC and E-IMD databases
(Table S3).
Residual enzymatic ASS1 activity correlates
with peak plasma ammonium and L-
citrulline concentrations during the first
metabolic decompensation
Since decreased ASS1 activity results in hyperammone-
mia and hypercitrullinemia, we first studied whether
NH4
+
max and peak plasma L-citrulline concentrations
during the first metabolic decompensation are associ-
ated with residual enzymatic ASS1 activity. Notably,
NH4
+
max inversely correlated with the underlying resid-
ual enzymatic ASS1 activity (n = 52, P < 0.001,
R2 = 0.29, GAM-analysis; Fig. 1A) as determined in the
mammalian biallelic expression system. Furthermore, we
identified a threshold distribution for individuals with
CTLN1 with a residual enzymatic ASS1 activity below
or equal to 8.1% exhibiting significantly higher
NH4
+
max at initial decompensation as opposed to
patients with a residual enzymatic ASS1 activity above
8.1% (n = 52, P < 0.001, recursive partitioning;
Fig. 1B). Even though patients with a residual enzy-
matic ASS1 activity below or equal to 8.1% have a
higher probability of developing NH4
+
max > 100 µmol/L
at initial decompensation, residual enzymatic activity
does not allow to reliably predict the exact height of
NH4
+
max within this group (Fig. 1A). However, also
peak plasma L-citrulline concentration showed an
inverse correlation with the underlying residual enzy-
matic ASS1 activity (n = 33, P < 0.001, R2 = 0.46,
GAM-analysis; Fig. 1C).
Residual enzymatic ASS1 activity correlates
with the disease severity and cognitive
outcome
Subsequently, we assessed whether residual enzymatic ASS1
activity correlates with the clinical disease course as indi-
cated by reported number of HAEs per year, NH4
+
max dur-
ing the most severe hyperammonemic decompensation and
the cognitive SDS of individuals with CTLN1 at their most
recent visit. Individuals with a residual enzymatic ASS1
activity below or equal to 8.1% not only had a significantly
higher number of HAEs per year (n = 43, P = 0.003, recur-
sive partitioning) and higher NH4
+
max during the most sev-
ere hyperammonemic decompensation (n = 26, P = 0.01,
recursive partitioning) (Fig. 2A–D), but also exhibited lower
cognitive function as opposed to individuals above this
threshold (n = 34, P = 0.031, recursive partitioning)
(Fig. 3A and B). Intriguingly, besides residual enzyme activ-
ity also age seems to affect cognitive functions since older
individuals with CTLN1 showed lower cognitive SDS than
younger individuals (Fig. 3C).
Residual enzymatic ASS1 activity is
associated with clinical outcome parameters
Given the above described correlations of residual
enzymatic ASS1 activity with the metabolic disease
course and cognitive outcome, we next investigated,
whether this observation also holds true for other clinical
features like movement disorder, tone change, hepatocellu-
lar injury, and kidney dysfunction. Indeed, residual enzy-
matic ASS1 activity is associated with the presence of
movement disorder and hepatocellular injury. Affected
individuals with a residual enzymatic ASS1 activity below
or equal to 19.3% suffer more often from movement dis-
orders (n = 60, P = 0.03, recursive partitioning; Fig. 4A).
This observation could be corroborated for the presence
of hepatocellular injury with a residual enzymatic
ASS1 activity of 3.9% as threshold (n = 55, P = 0.039,
recursive partitioning; Fig. 4B). However, residual
enzymatic ASS1 activity did not discriminate between
1862 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Phenotypic Prediction in Citrullinemia Type 1 M. Zielonka et al.
individuals with or without tone changes (n = 65,
P = 0.16, t-test) neither between CTLN1-individuals
with (FAS-GFR < 90 mL/min/1.73 m2) or without
(FAS-GFR ≥ 90 mL/min/1.73 m2) reported episodes of
impaired kidney function (n = 47, P = 0.44, t-test).
Empiric clinical practice reflects disease
severity
Since residual enzymatic ASS1 activity predicts the
disease course and clinical outcome in CTLN1, we
Figure 1. Residual enzymatic ASS1 activity correlates with initial biochemical parameters. (A) NH4
+
max (µmol/L) subject to residual enzymatic ASS1
activity (%) as determined in the biallelic expression system. Each point represents a single patient (n = 52). Gray line displays estimated
regression curve. GAM-analysis, P < 0.001, R2 = 0.29. (B) Boxplot illustrating NH4
+
max (µmol/L) with a residual enzymatic ASS1 activity below or
equal to 8.1% (n = 32) and above 8.1% (n = 20). Data are shown as median (black thick line) and mean (triangle), length of the box
corresponds to interquartile range (IQR), upper and lower whiskers correspond to max. 1.5 9 IQR, each point represents an outlier. Recursive
partitioning, P < 0.001. (C) Peak plasma L-citrulline concentration subject to residual enzymatic ASS1 activity (%). Each point represents a single
patient (n = 33). Gray line displays estimated regression curve. GAM-analysis, P < 0.001, R2 = 0.46. ASS1, argininosuccinate synthetase 1.
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tested whether the current clinical practice as indicated
by LTx status and implementation of special education
in the management might also correlate with residual
enzymatic ASS1 activity. In fact, individuals with a
residual enzymatic ASS1 activity below or equal to
4.8% underwent LTx more often than those with
Figure 2. Residual enzymatic ASS1 activity predicts number and severity of HAEs. (A) Number of HAEs (NH4
+
max ≥ 100 µmol/L) per year subject
to residual enzymatic ASS1 activity (%). Each point represents a single patient (n = 43). Gray line displays estimated regression curve. GAM-
analysis, P = 0.002, R2 = 0.26. (B) Boxplot illustrating number of HAEs (NH4
+
max ≥ 100 µmol/L) per year with a residual enzymatic ASS1 activity
below or equal to 8.1% (n = 17) or above 8.1% (n = 26). Data are shown as median (black thick line) and mean (triangle), length of the box
corresponds to IQR, upper and lower whiskers correspond to max. 1.5 9 IQR, each point represents an outlier. Recursive partitioning, P = 0.003.
(C) NH4
+
max during most severe HAE subject to residual enzymatic ASS1 activity (%). Each point represents a single patient (n = 26). Gray line
displays estimated regression curve. GAM-analysis, P = 0.007, R2 = 0.23. (D) Boxplot illustrating NH4
+
max during most severe HAE with a residual
enzymatic ASS1 activity below or equal to 8.1% (n = 17) or above 8.1% (n = 9). Data are shown as median (black thick line) and mean
(triangle), length of the box corresponds to IQR, upper and lower whiskers correspond to max. 1.5 9 IQR, each point represents an outlier.
Recursive partitioning, P = 0.01. ASS1, argininosuccinate synthetase 1.
1864 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Phenotypic Prediction in Citrullinemia Type 1 M. Zielonka et al.
higher activity (n = 71, P = 0.011, recursive partitioning;
Fig. 5A). Noteworthy, individuals with a residual enzy-
matic ASS1 activity above 10% did not undergo LTx
during the observation period at all. Furthermore,
individuals with a residual enzymatic ASS1 activity
below or equal to 26.6% received special education
support more frequently (n = 38, P < 0.001, recursive
partitioning; Fig. 5B) than above this threshold.
Figure 3. Residual enzymatic ASS1 activity correlates with cognitive outcome. (A) Cognitive SDS subject to residual enzymatic ASS1 activity (%).
Each point represents a single patient (n = 34). Grey line indicates linear regression curve. Linear regression, P = 0.029, R2 = 0.14. (B) Boxplot
illustrating cognitive SDS with a residual enzymatic ASS1 activity below or equal to 8.1% (n = 13) and above 8.1% (n = 21). Data are shown as
median (black thick line) and mean (triangle), length of the box corresponds to IQR, upper and lower whiskers correspond to max. 1.5 9 IQR.
Recursive partitioning, P = 0.031. (C) Levelplot for cognitive SDS, residual enzymatic ASS1 activity and age at testing (years). Cognitive SDS values
are indicated by color coding in grading from blue to red with descending cognitive SDS. ASS1, argininosuccinate synthetase 1.
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Discussion
A novel mammalian biallelic expression
system predicts the functional
consequences of pathogenic ASS1 variants
Using a newly established mammalian biallelic expression
system for the quantitative analysis of residual enzymatic
ASS1 activity based on pathogenic ASS1 variants reported
in the UCDC and E-IMD registries, we show, that resid-
ual enzymatic ASS1 activity reliably predicts the clinical
disease course and cognitive outcome in CTLN1. Individ-
uals with a residual enzymatic ASS1 activity below or
equal to 8% experience a higher number and more severe
HAEs, and have a lower cognitive outcome at most recent
visit.
The established mammalian biallelic expression system
combines the overexpression of patient-specific variants
in ASS1 proteins in COS-7 cells and the quantification of
residual enzymatic ASS1 activities in cell lysates 48 h after
transfection applying a novel coupled ASS1 enzyme assay.
Intriguingly, the residual enzymatic ASS1 activities as
determined by our assay show a correlation with bio-
chemical and clinical endpoints, thereby confirming that
the modelling approach quantitatively reflects the protein
dysfunction in individuals with CTLN1. This observation
might owe to the overexpression strategy of equimolar
transfection of both (homozygous/compound heterozy-
gous) ASS1 expression vectors, which as a consequence
most likely leads to an equimolar expression of the (mu-
tated) proteins (encoded by both alleles), mimicking the
endogenous situation in individuals with CTLN1. The
utilized COS-7 cell line has been used as overexpression
system for the investigation of protein (dys-) functions
for more than three decades including the quantification
of residual activities of enzymes of intermediary metabo-
lism.20 Coupled enzyme assays have been successfully
established and are widely used for the reliable determina-
tion of activities of glycolytic or TCA cycle enzymes as
well as respiratory chain complexes, which allow the real-
time quantification of activity rates by exploiting redox-
reactions of redox-active coenzymes such as NAD or
FAD.21–23 This strategy also proved effective for the quan-
titative analysis of residual enzymatic ASS1 activity in our
study. The established mammalian biallelic assay system is
a non-invasive modelling approach, which enables the
systematic investigation of the cumulative effect of
reported homozygous and most importantly compound
heterozygous mutations within the ASS1 gene in a stan-
dardized and time-efficient manner on a highly discrimi-
native scale, in particular for low residual enzymatic ASS1
activities.
Figure 4. Residual enzymatic ASS1 activity predicts organ-specific manifestations. (A) Boxplot illustrating presence of movement disorders (%) for
individuals with a residual enzymatic ASS1 activity below or equal to 19.3% (n = 34) and above 19.3% (n = 26). Gray shading corresponds to
individuals with movement disorders in each group. Recursive partitioning, P = 0.03. (B) Boxplot displaying presence of hepatocellular injury (%)
for individuals with a residual enzymatic ASS1 activity below or equal to 3.9% (n = 7) and above 3.9% (n = 48). Gray shading corresponds to
individuals with episode(s) of hepatocellular injury in each group. Recursive partitioning, P = 0.039. ASS1, argininosuccinate synthetase 1.
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From bench to bedside – modelling
evidence-based thresholds for clinical
endpoints
The subsequent correlation analysis between residual
enzymatic ASS1 activity and biochemical, clinical as well
as organ-specific endpoints is prototypic for UCDs and a
powerful tool for individuals with CTLN1 since (1) it
identifies robust cut-offs of residual enzymatic ASS1
activity for the prediction of clinical outcomes, (2) it
might serve as a tool for physicians in counselling of
patients and their families, (3) it is a prerequisite for the
development of risk-stratified, individualized concepts for
therapy and care, (4) it is likely to be causally related to
the disease course and neurological outcome, and (5) it
reduces bias and misinterpretation of future studies aim-
ing at evaluating the impact of newborn screening pro-
grams and innovative therapies on the health outcomes of
affected individuals.
Interestingly, residual enzymatic ASS1 activity of 8% or
less is associated with a higher NH4
+
max at initial decom-
pensation, and a higher number and severity of HAEs. This
is of importance, since these parameters have recently been
reported as major risk factors for a poor outcome.5,7,8,24,25
Intriguingly, individuals with CTLN1 and a residual enzy-
matic ASS1 activity of 8% or less develop approximately
1.25 HAEs per year despite adequate conventional meta-
bolic therapy, whereas this is not the case for those with
higher residual enzymatic ASS1 activity suffering from
HAEs only once every 12.5 years in mean. However, there
are single individuals who do also show high NH4
+
max at
initial decompensation with a maximum of approx.
880 µmol/L (Fig. 1B and Table S1) and do decompensate
once per year at maximum despite residual enzymatic ASS1
activity higher than 8% (Fig. 2B and Table S1), which
needs to be taken into account by physicians for the clinical
management of these patients. Importantly, the threshold
of 8% is also reflected by the susceptibility to suffer from
an impaired cognitive outcome.
Given known variables of an unfavorable clinical out-
come (such as initial NH4
+
max, number and severity of
HAEs) and an evidence-based cut-off value of 8% or
below predicting a poor cognitive outcome, we propose
residual enzymatic ASS1 activity of 8% or below, as
assessed by our system, as a reasonable threshold for dis-
criminating individuals with a severe (≤ 8%) or mild-to-
moderate (> 8%) clinical phenotype. This is corroborated
by the finding that in our cohort only one CTLN1-indi-
vidual above 8% residual enzymatic ASS1 activity under-
went LTx. Of note, the reported thresholds as determined
by our standardized assay might slightly differ for the
investigated mutations when compared to other methods.
Figure 5. Decision for liver transplantation and special education reflects risk-stratification by residual enzymatic ASS1 activity. (A) Boxplot
illustrating proportion of individuals (%) with a liver graft for those with a residual enzymatic ASS1 activity below or equal to 4.8% (n = 13) and
above 4.8% (n = 58). Grey shading corresponds to individuals with liver graft in each group. Recursive partitioning, P = 0.011. (B) Boxplot
displaying proportion of individuals (%) with special education for those with a residual enzymatic ASS1 activity below or equal to 26.6%
(n = 26) and above 26.6% (n = 12). Gray shading corresponds to individuals with special education in each group. Recursive partitioning,
P < 0.001. ASS1, argininosuccinate synthetase 1.
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Even though residual enzymatic ASS1 activity correlates
well with the overall clinical disease course and cognitive
outcome of CTLN1-individuals, the positive predictive
value does not reach 100% for any analyzed clinical vari-
able. For the cognitive outcome, 46% of patients with a
residual enzymatic ASS1 activity below the threshold of
8% have a cognitive SDS below or equal to 2, whereas
54% of patients perform better in cognitive testing. The
observation, that clinical manifestations are not present in
all individuals below the defined thresholds of residual
enzymatic ASS1 activity can also be corroborated for fur-
ther outcome variables, such as movement disorder, and
hepatocellular injury. These findings indicate alternative
modifying disease mechanisms apart from residual enzy-
matic ASS1 activity underlying the clinical course of
CTLN1-individuals. Notably, the enzyme ASS1 has
recently been identified as potential RNA-binding protein
in RNA interactome capture.26 These newly identified
RNA-binding properties of ASS1 might be implicated in
the pathophysiology of CTLN1, which needs to be
addressed in future research. Moreover, the observation
that residual enzymatic ASS1 activity does not allow to
predict the exact NH4
+
max at initial decompensation as
well as the exact number of HAEs within the group of
patients below the threshold of 8% indicates that –
besides residual enzymatic activity – further precipitating
factors (e.g., severity of catabolic state, delay between first
symptoms and treatment initiation, compliance to long-
term treatment) might determine the severity of meta-
bolic decompensations, as reflected by the scattered data
in this group. Another possible explanation might be, that
a subset of patients have “leaky mutations” associated
with altered kinetic properties (Km mutations) due to
decreased substrate binding of the ASS1 enzyme,27 which
needs to be addressed in future research.
Residual enzymatic ASS1 activity qualifies
as predictive biomarker for individuals with
CTLN1
Biomarkers are defined to reflect the activity of a disease
process and can be of diagnostic, prognostic, predictive,
or pharmacodynamic nature.28,29 Specifically, residual
enzymatic ASS1 activity as determined in our mammalian
biallelic expression system can be considered a prognostic
and predictive biomarker based on the present findings.
In contrast, biomarkers serving as truly validated surro-
gate markers are required to capture the severity of dis-
ease, which is the case for residual enzymatic ASS1
activity, but in addition need to reflect the net effect of
treatment on the true outcome.30 Since there are cur-
rently no specific therapies available, which aim at
increasing the residual enzymatic activity of the ASS1
enzyme in CTLN1, the latter requirement of demonstrat-
ing the reflection of net treatment effects is not possible
at the current time. Nevertheless, the identification that
the clinical disease course and cognitive outcome clearly
correlates with the residual enzymatic ASS1 activity is
encouraging and might stimulate future drug develop-
ment. Increasing the residual enzymatic ASS1 activity
above a threshold of 8% (e.g., by application of chaper-
ones or antisense nucleotides targeting aberrant splicing
of the precursor mRNA to increase the level of normally
translated protein) as demonstrated for other inherited
diseases might have a major beneficial effect on the dis-
ease course, by reducing the number and severity of
HAEs, and by improving the cognitive and hepatic func-
tion of affected individuals with CTLN1 as implicated by
our data.31,32
Preliminary data suggest that height of the initial peak
plasma L-citrulline concentration inversely correlates with
residual enzymatic ASS1 activity (Fig. S4), which has to
be proven in future prospective trials, in particular with
regard to L-citrulline concentrations determined in dried
blood spots during newborn screening. Furthermore, our
functional data propose a new severity-adjusted classifica-
tion system for individuals with CTLN1, which has to be
regarded complementary to the current classification
based on the onset type (Fig. S5). Importantly, clinicians
should be aware that patients who are defined asymp-
tomatic to date might develop symptoms over time,
which has already been described for urea cycle disor-
ders.2 Further intra-individual long-term data will enable
to determine to which extent this also applies for the
investigated study cohort.
Limitations
This study has some inherent limitations. Only exonic
mutations have been modelled and investigated, due to
the applied technique of cloning the coding sequence of
the ASS1 gene into the mammalian expression vector,
which does not allow the investigation of intronic muta-
tions associated with defective splicing. Our analysis does
not claim to systematically investigate the underlying
pathomechanisms of specific mutations leading to
decreased residual enzymatic ASS1 activity on an individ-
ual level (e.g., impaired protein folding, decreased protein
stability, etc.). Figures S1 and S2 depicting results of qRT-
PCR data and protein expression levels as determined by
Western blot analysis should be considered exploratory
and might serve as a basis for future detailed investiga-
tions regarding underlying mechanisms of reduced resid-
ual enzymatic ASS1 activity for each mutation. Moreover,
in light of potential disease progression in CTLN1 over
time further intra-individual long-term data is necessary
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to substantiate our findings, in particular with regard to
progressive cognitive deterioration in older (or asymp-
tomatic) individuals with CTLN1.
Conclusion
Based on the biallelic expression system, we propose a
new severity-adjusted classification system for individuals
with CTLN1 having a severe (residual enzymatic ASS1
activity ≤ 8%) and mild-to-moderate (residual enzymatic
ASS1 activity > 8%) phenotype, which is to be regarded
complementary to the currently existing clinical classifica-
tion system for CTLN1. Future analyses will prove, if an
intermediate phenotype might be identified in the group
of CTLN1-individuals with residual enzymatic ASS1 activ-
ity above 8%. Given the evident impact of the present
method for the prediction of the clinical disease course
and cognitive outcome, we are hopeful that this mod-
elling approach can be applied to other inborn errors of
metabolism.
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per variant combination.
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ant combination.
Figure S3. Overview of residual enzymatic ASS1 activities
per variant combination.
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Figure S4. Peak plasma L-citrulline concentration (at ini-
tial decompensation) reflects residual enzymatic ASS1
activity (%).
Figure S5. Correlation between disease onset (EO, LO,
Asymptomatic) and residual enzymatic ASS1 activity (%).
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Table S2. Descriptive characteristics for correlation analy-
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Table S3. Comparison of residual enzymatic ASS1 activity
determined in the biallelic expression system and patient
fibroblasts.
Table S4. Additional members and affiliations of the
UCDC and E-IMD consortia study group.
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 1871
M. Zielonka et al. Phenotypic Prediction in Citrullinemia Type 1
